ClinicalTrials.gg
CompletedNCT02019381Updated Dec 22, 2016

Study the Effects of Vitamin D and Calcium Supplementation at Tolerable Upper Limit Doses on Calcium Metabolism.

An interventional study of Endocrine Society UL Dosage Vitamin D and Institute of Medicine Dosage Vitamin D in Delusion of Reference, sponsored by Winthrop University Hospital. Completed at 1 site in United States. Open to female participants aged 50 Years to 90 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-12-22.

Sponsored by Winthrop University Hospital · Not applicable, Interventional, and Health services research

Phase
Not applicable
Study type
Interventional
Enrollment
132
Allocation
Randomized
Ages
50 Years to 90 Years
Sex
Female
01

Study summary

Recently two distinguished committees, Institute of Medicine (IOM) and The Endocrine Society have proposed different intake guidelines for Calcium and Vitamin D. We wish to compare the effects of both of them on calcium metabolism and bone turnover. We propose a one year randomized double blinded study for the same.

Read the detailed description

The specific aims of this study proposal are to determine the following:

  1. To compare the two different intake guidelines for Calcium and Vitamin D Supplementation at its recommended tolerable upper limit on serum and urinary calcium in white postmenopausal Women.
  2. Compare the effects above mentioned two intake guidelines on Vitamin D metabolism [25(OH)D, 1,25(OH)2D] and bone turnover.

Participants will be randomly assigned to Group A or Group B based on different dosages of study medications.

Group A: 10,000 IU (International Units)Vitamin D + Placebo (sugar pill) 600IU Vitamin D + Two pills Calcium containing 600mg calcium each.

Group B: 600 IU Vitamin D + Placebo (sugar pill) 10,000 IU Vitamin D

  • Two pills Calcium containing 600mg calcium each.

In addition to the calcium supplements, they will guide to include approximately 800mg of calcium in their daily diet.

At visit 2, fasting blood and spot urine will be collected. A urinal will be dispensed for collection of 24-hour urine for urinary calcium to be brought in next day. Study medication will be dispensed and participants will be asked not to discard unused medications and to bring all study medications next study visit.

Visit 3, 4, 5, 6 will essentially be the same as visit 2, with subjects returning unused study medication and given new tablets each visit. Except on visit 6 no further study medications will be dispensed, after collecting the previous supply.

Food frequency questionnaires will be filled out at the initial visit and final visit. Diet will be assessed using 3-day diet history form and Nutrition Pro analysis software. Patients will be asked to refrain from taking other Vitamin D supplements and to continue their usual calcium intake.

02

Conditions studied

  • Delusion of Reference

Browse trials for

03

In context

Delusions

32 studies on the registry are indexed under Delusions; 8 are open to participants now.

This study's enrollment of 132 is above the median of 94 across 28 interventional studies indexed under Delusions.

Browse Delusions studies →

Lead sponsor

Winthrop University Hospital is the lead sponsor of 42 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
50 Years to 90 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy White women aged 50 and older who have been for at least 2 year (i.e. absence of menstrual period for a period of 24 months or more).
  2. Willingness to discontinue self-administration of vitamin D and calcium supplements. Participants must be at least three months off supplements before starting the study.
  3. Willingness to take study medications and participate in study for one year.
  4. Written Signed.
  5. Patients with hypertension and diabetes stable for last three months.

Exclusion criteria

Exclusion Criteria:

  1. History of hypercalciuria (24-hour urinary calcium excretion >250 mg), hypercalcemia (serum calcium >10.6), nephrolithiasis and active sarcoidosis will be excluded.
  2. Serum 25-hydroxyvitamin D level >80 nmol/L or history of primary hyperparathyroidism.
  3. Dietary calcium intake of >2000mg/day will be excluded
  4. Use of medication that influences bone or vitamin D metabolism (e.g. anticonvulsant medications, , Highly Active AntiRetroviral Therapy [AIDS treatment], antirejection medications, chronic use of steroids, high dose diuretics)
  5. Treatment with Hormone replacement therapy, Selective Estrogen Receptor Modulators, Calcitonin, Parathyroid hormone , androgens, bisphosphonates, phosphate or anabolic steroids 6 months prior to the study.
  6. Use of systemic steroids (oral or intravenous) within the last year at an average dose of more than 5mg/day of oral prednisone or an equivalent for a period of three months or more prior to screening.
  7. Chronic medical illness including Chronic liver disease, uncontrolled diabetes mellitus; recent history of myocardial infarction or heart failure; newly diagnosed or active ; uncontrolled hypertension; obesity (>35 kg/m2); malabsorption, anemia, leukemia, or other hematologic abnormalities; lupus, rheumatoid arthritis, sarcoidosis, or other rheumatologic disease; chronic kidney disease, metabolic bone disease.
  8. Unexplained weight loss of >15% during the previous year or history of anorexia nervosa
  9. > 1 pack per day tobacco use or > 2 alcoholic beverages per day
  10. Unwillingness to forego self-administration of vitamin D and calcium-containing supplements.
  11. Participation in another trial in the past 30 days prior to the screening evaluation
  12. Significant deviation from normal in medical history, physical examination, or laboratory tests as evaluated by the primary investigator.
  13. Patients with unstable hypertension or diabetes.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
132 participants (actual)

Study arms

  • Other
    Endocrine Society UL Dosage Vitamin D

    Participants will be randomly assigned vitamin D + calcium dose based on Endocrine Society Upper limit guidelines. And given 10,000IU Vitamin D + 1200mg Calcium (600IU Placebo Vitamin D, in addition to two calcium tablets of 600mg) each to be taken per day.

    Dietary Supplement: Endocrine Society UL Dosage Vitamin D · Dietary Supplement: Calcium

  • Other
    Institute of Medicine Dosage Vitamin D

    Participants will be randomly assigned Vitamin D dose based on IOM guidelines; calcium dose will be as per IOM upper limits. And will receive 600 IU Vitamin D + 1,200 mg of calcium tablets to be taken per day.

    Dietary Supplement: Institute of Medicine Dosage Vitamin D · Dietary Supplement: Calcium

Interventions

  • Dietary supplementEndocrine Society UL Dosage Vitamin D

    Endocrine Upper limit arm will get 10,000IU Vitamin D and 1200mg Calcium

  • Dietary supplementInstitute of Medicine Dosage Vitamin D

    IOM arm will get 600 IU Vitamin D and 1,200 mg Calcium

  • Dietary supplementCalcium

    1200mg of CaCO3 supplementation will be given to each participant in both groups

06

What researchers measure

Primary outcomes

  1. Compare the effects of 10000 IU/day vitamin D plus 2,000 mg/day calcium versus 600 IU/day vitamin D plus 2,000 mg/day calcium on incidence of hypercalciuria (spot urine calcium:creatinine ratio, 24-hour urine calcium).

    Endocrine society has recommended tolerable upper limit or a dose with no adverse events as 10,000IU of Vitamin D and 2000 mg/day of calcium. Our study will test the safety/ efficacy of this recommendation.

    Time frame: One year

Secondary outcomes

  1. Compare the effects of 10,000 IU/day vitamin D plus 2,000 mg/day calcium versus 600 IU/day vitamin D plus 2,000 mg/day calcium on vitamin D metabolism [25(OH)D, 1,25(OH)2D], and bone turnover.

    To test safety/efficacy of The Endocrine Society recommendations on Bone turnover.

    Time frame: One year

07

Study locations

1 site
  • Winthrop University Hospital
    Mineola, New York 11501, United States
08

References and documents

Publications

  • Aloia JF, Katumuluwa S, Stolberg A, Usera G, Mikhail M, Hoofnagle AN, Islam S. Safety of calcium and vitamin D supplements, a randomized controlled trial. Clin Endocrinol (Oxf). 2018 Dec;89(6):742-749. doi: 10.1111/cen.13848. Epub 2018 Oct 1. PubMed 30180273 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2013, a primary completion of Jun 2016 and a completion of Jun 2016. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 12, 2013
First posted
Dec 24, 2013
Start
Sep 2013
Primary completionActual
Jun 2016
CompletionActual
Jun 2016
Last update
Dec 22, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 22, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02019381
Lead sponsor
Winthrop University Hospital
Responsible party
John F. Aloia, MD (Chief Academic Officer, MD, Endocrinology., Winthrop University Hospital) — Principal investigator
First posted
Dec 24, 2013
Start date
Sep 2013
Primary completion
Jun 2016
Completion
Jun 2016
Last update
Dec 22, 2016

Study contacts

John Aloia, MD
principal investigator · Winthrop UH
Mageda Mikhail, MD
study director · Winthrop UH

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion